MARKET

CELC

CELC

Celcuity Inc
NASDAQ
67.05
-3.32
-4.72%
After Hours: 67.05 0 0.00% 19:30 11/10 EST
OPEN
68.96
PREV CLOSE
70.37
HIGH
71.00
LOW
66.19
VOLUME
769.80K
TURNOVER
--
52 WEEK HIGH
151.02
52 WEEK LOW
53.54
MARKET CAP
3.29B
P/E (TTM)
-14.2463
1D
5D
1M
3M
1Y
5Y
1D
Celcuity announces FDA acceptance of sNDA for Revtorpyk
TipRanks · 1d ago
Celcuity's Supplemental New Drug Application For REVTORPYK Accepted for FDA Review To Treat Hormone Receptor Positive
Benzinga · 1d ago
Block To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 1d ago
Is Celcuity (CELC) Undervalued After Its Q3 Loss Raised Fresh Questions?
Simply Wall St · 1d ago
Celcuity Price Target Cut to $150.00/Share From $155.00 by HC Wainwright & Co.
Dow Jones · 1d ago
Celcuity Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Celcuity, Lowers Price Target to $150
Benzinga · 1d ago
Weekly Report: what happened at CELC last week (1102-1106)?
Weekly Report · 1d ago
More
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.

Webull offers Celcuity Inc stock information, including NASDAQ: CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELC stock methods without spending real money on the virtual paper trading platform.